99 related articles for article (PubMed ID: 23906537)
1. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer.
Rocha J; Zouanat FZ; Zoubeidi A; Hamel L; Benidir T; Scarlata E; Brimo F; Aprikian A; Chevalier S
Mol Cell Endocrinol; 2013 Dec; 381(1-2):140-9. PubMed ID: 23906537
[TBL] [Abstract][Full Text] [Related]
2. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.
Zoubeidi A; Rocha J; Zouanat FZ; Hamel L; Scarlata E; Aprikian AG; Chevalier S
Mol Cancer Res; 2009 Jan; 7(1):142-55. PubMed ID: 19147545
[TBL] [Abstract][Full Text] [Related]
3. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
4. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.
Lee LF; Louie MC; Desai SJ; Yang J; Chen HW; Evans CP; Kung HJ
Oncogene; 2004 Mar; 23(12):2197-205. PubMed ID: 14767470
[TBL] [Abstract][Full Text] [Related]
6. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain.
Hua Y; Azeem W; Shen Y; Zhang S; Olsen JR; Øyan AM; Ke X; Zhang W; Kalland KH
Pharmacol Res Perspect; 2018 Dec; 6(6):e00437. PubMed ID: 30410767
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor.
Hobisch A; Eder IE; Putz T; Horninger W; Bartsch G; Klocker H; Culig Z
Cancer Res; 1998 Oct; 58(20):4640-5. PubMed ID: 9788616
[TBL] [Abstract][Full Text] [Related]
8. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
9. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus.
Kim J; Jia L; Stallcup MR; Coetzee GA
J Mol Endocrinol; 2005 Feb; 34(1):107-18. PubMed ID: 15691881
[TBL] [Abstract][Full Text] [Related]
10. [The concept and mechanisms of castration-resistant prostate cancer].
Naito S; Shiota M
Nihon Rinsho; 2014 Dec; 72(12):2090-4. PubMed ID: 25518339
[TBL] [Abstract][Full Text] [Related]
11. Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo Z; Dai B; Jiang T; Xu K; Xie Y; Kim O; Nesheiwat I; Kong X; Melamed J; Handratta VD; Njar VC; Brodie AM; Yu LR; Veenstra TD; Chen H; Qiu Y
Cancer Cell; 2006 Oct; 10(4):309-19. PubMed ID: 17045208
[TBL] [Abstract][Full Text] [Related]
12. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
Sanford DC; DeWille JW
Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
[TBL] [Abstract][Full Text] [Related]
13. An androgen-IL-6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells.
Aaronson DS; Muller M; Neves SR; Chung WC; Jayaram G; Iyengar R; Ram PT
Mol Cell Endocrinol; 2007 May; 270(1-2):50-6. PubMed ID: 17374439
[TBL] [Abstract][Full Text] [Related]
14. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
Gong J; Zhu J; Goodman OB; Pestell RG; Schlegel PN; Nanus DM; Shen R
Oncogene; 2006 Mar; 25(14):2011-21. PubMed ID: 16434977
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
[TBL] [Abstract][Full Text] [Related]
16. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
18. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T
Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566
[TBL] [Abstract][Full Text] [Related]
19. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
20. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines.
Paliouras M; Diamandis EP
Biol Chem; 2008 Jun; 389(6):773-80. PubMed ID: 18627304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
